Sponsors

ITOC12 thankfully acknowledges the support of the following companies and institutions

(listing in alphabetical order)

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

EUR 9.500,-

Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer. Read more: https://www.gileadsciences.de/

EUR 3.500,-

Johnson & Johnson In Germany, J&J Innovative Medicine has about 1,000 employees and is the number 2 among research-based pharmaceutical companies.

Every day, J&J invests around 37.1 million U.S. dollars worldwide in the research and development of new drugs, including in the fields of oncology, immunology and neuroscience. 15 of the company's active ingredients are on the 23rd WHO Model List of Essential Medicines. In 2024, approximately 500,000 patients in Germany were treated with a prescription product from J&J.

EM-159888

EUR 27.000,-

MedChemExpress (MCE) is a supplier of research chemicals and bioactive compounds with 10+ warehouses worldwide. It offers 100,000+ high-quality inhibitors/agonists targeting 1,000+ proteins across 20+ pathways, alongside recombinant proteins, dyes, and assay kits. MCE provides custom synthesis (ADCs, PROTACs) and a comprehensive drug discovery platform featuring 200+ compound libraries, advanced screening (HTS, AI), and profiling services to support global research.

EUR 3.800,-

Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, transforming scientific discoveries into practical treatments for personalized medicine. With over 35 years of expertise, it supports biomedical discoveries and translates them into clinical applications, enhancing patient access to new therapies. Miltenyi Biotec focuses on offering integrated solutions for complex challenges in treating cancers, autoimmune diseases, and inherited disorders. Its Miltenyi Bioindustry division provides expert guidance to therapy developers efficiently from process development to commercialization. Headquartered in Bergisch Gladbach, it employs 4,700 people across 24 countries.

EUR 3.800,-

Pixelgen Technologies AB is on a mission to deliver biology at the highest resolution by understanding the molecular basis of cellular function with new tools and technologies that decipher the protein interactomics of single cells in unprecedented ways. The company’s patented Proximity Network Assay delivers nanoscale spatial analysis of immune cell proteins at ultra-high capacity and underpins the Pixelgen Proxiome Kit for precision medicine. Pixelgen was founded in 2020 by a team of passionate, experienced innovators and entrepreneurs and is venture-backed.

EUR 5.300,-

MedChemExpress (MCE) is a supplier of research chemicals and bioactive compounds with 10+ warehouses worldwide. It offers 100,000+ high-quality inhibitors/agonists targeting 1,000+ proteins across 20+ pathways, alongside recombinant proteins, dyes, and assay kits. MCE provides custom synthesis (ADCs, PROTACs) and a comprehensive drug discovery platform featuring 200+ compound libraries, advanced screening (HTS, AI), and profiling services to support global research.

EUR 3.800,-

Wolfgang Wilmanns Stiftung

The purpose of the Wolfgang Wilmanns Foundation is the support of leukaemia and tumour research at the universities in Munich with the involvement of the TZM. This purpose is particularly fulfilled through awarding prizes to young researchers or research groups at the universities in Munich for outstanding performance in this area. The foundation is a non-profit organisation. Click to read more.

EUR 1.000,-

We herewith confirm that all sponsorship income is free of any attempt to influence the programme, individual sessions, subjects for discussions, content or choice of faculty members